Abeona therapeutics announces multiple abstracts accepted from its aav ophthalmology program at the 26th annual meeting of the american society of gene & cell therapy (asgct)

Cleveland, april 10, 2023 (globe newswire) -- abeona therapeutics inc. (nasdaq: abeo) today announced the acceptance of three abstracts at the 26th annual meeting of the american society of gene & cell therapy (asgct) taking place from may 16-20, 2023 in los angeles, ca. accepted abstracts include new data on three internally developed investigational preclinical gene therapy product candidates from its adeno-associated virus (aav) ophthalmology program, including abo-504 for stargardt disease, abo-503 for x-linked retinoschisis (xlrs) and abo-505 for autosomal dominant optic atrophy (adoa).
ABEO Ratings Summary
ABEO Quant Ranking